The fixed-dose combination of olanzapine and fluoxetine (
Symbyax - Lilly) has been approved by the FDA for treatment of depressive episodes associated with bipolar disorder. Olanzapine alone (
Zyprexa), which is mainly used as an antipsychotic (
Medical Letter 2003; 45:102), is FDA-approved for treatment of acute manic episodes and for maintenance treatment of bipolar disorder. Fluoxetine alone (
Prozac, and others), which is mainly used as an antidepressant (
Medical Letter 2003; 45:93), has no specific approval for use in bipolar disorder....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to
The Medical Letter on Drugs and Therapeutics, please
login or
register to view it online.
If you have already purchased this article, or have a subscription to
The Medical Letter on Drugs and Therapeutics, please
login or
register to view it online.
Information about the article:
Title: Olanzapine/Fluoxetine (Symbyax) for Bipolar Depression
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1178
Article Code: 1178c
Date: March 15, 2004
Volume: 46
Pages: 23-24